The massive overhang from Armistice's potential selling will pressure AMIX shares. Monitor for any 424B prospectus supplements indicating actual sales. The company's going concern status and repeated dilutive financings suggest further capital raises are likely. Traders should watch for any Nasdaq compliance issues if the stock price weakens.
Price Chart
Executive Summary
Autonomix Medical filed an S-3 to register 1,071,826 shares for resale by Armistice Capital Master Fund, issued as Series E warrants at $6.25/share in an August 2026 warrant inducement. The company received $4.9M from the exercise of existing warrants but gets no proceeds from this resale registration. With only 1,828,505 shares outstanding, the registered shares represent ~58.6% potential dilution, creating a massive overhang on a $9M market cap company already flagged with a going concern opinion.
Key Financial Metrics
Key Facts
- Registers 1,071,826 shares for resale by Armistice Capital Master Fund Ltd.
- Shares are issuable upon exercise of Series E warrants at $6.25 per share.
- Company received ~$4.9M gross from the warrant inducement but no proceeds from this S-3.
- Outstanding shares as of Aug 31, 2026: 1,828,505 — registered shares equal ~58.6% dilution.
- Auditor's report contains a going concern explanatory paragraph.
- Company is a development-stage medical device firm with a $9M market cap.
Financial Impact
Potential dilution of ~58.6% from full warrant exercise; maximum cash proceeds to company of ~$6.7M if all warrants exercised for cash, but cashless exercise is permitted after six months.
Risk Factors
- Armistice Capital may sell aggressively, depressing the stock price.
- Going concern opinion raises risk of equity raise at distressed levels or delisting.
- Warrants exercisable on cashless basis after six months — company may receive no additional cash.
- Multiple prior shelf filings indicate chronic capital needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001437749-26-029712 |
| Exhibit: ex_1011086.htm | 0001437749-26-029712 |
| Exhibit: ex_1011084.htm | 0001437749-26-029712 |
| Exhibit: ex_1011085.htm | 0001437749-26-029712 |
| Document: 0001437749-26-029712-index-headers.html | 0001437749-26-029712 |
| Document: 0001437749-26-029712-index.html | 0001437749-26-029712 |
| Document: 0001437749-26-029712.txt | 0001437749-26-029712 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 3 | $3.01 | awaiting T+20 | — | $2.15 (−28.57%) |
Oct 2, 2026 24d ago | Press Release | $3.78 | awaiting T+20 | — | $2.15 (−43.12%) |
Sep 16, 2026 5w ago | 8-K | $4.12 $3.01 | ▼ −26.94% | ▼ −30.12% | $2.15 (−47.82%) |
Sep 16, 2026 5w ago | EFFECT | $4.12 $3.01 | ▲ +26.94% | ▲ +30.12% | $2.15 (+47.82%) |
Sep 11, 2026 6w ago | 424B5 | $4.33 $3.10 | ▲ +28.41% | ▲ +30.67% | $2.15 (+50.35%) |
Sep 4, 2026 7w ago | S-3 | $4.58 $3.47 | ▲ +24.24% | ▲ +25.95% | $2.15 (+53.06%) |
Aug 26, 2026 8w ago | 8-K | $5.63 $4.07 | ▼ −27.71% | ▼ −27.20% | $2.15 (−61.81%) |
Aug 5, 2026 11w ago | EFFECT | $12.10 $4.50 | ▼ −62.81% | ▼ −62.21% | $2.15 (−82.23%) |
Jul 28, 2026 12w ago | 8-K | $2.75 $7.19 | ▲ +161.45% | ▲ +158.07% | $2.15 (−21.82%) |
Jul 15, 2026 14w ago | 8-K | $4.92 $6.86 | ▼ −39.43% | ▼ −35.81% | $2.15 (+56.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers